Lenacapavir for HIV-1 Infection
Indications
Lenacapavir is FDA-approved for two distinct indications: (1) treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 infection when their current regimen is failing, and (2) pre-exposure prophylaxis (PrEP) to prevent sexually acquired HIV-1 infection in adults and adolescents ≥35 kg at risk for HIV acquisition 1, 2.
For treatment, lenacapavir must be combined with other antiretrovirals as part of an optimized background regimen (OBR). It is specifically reserved for patients with documented multidrug resistance, treatment failure, or intolerance to other agents 1, 3. In the treatment setting, 62-82% of heavily treatment-experienced patients achieved viral suppression (<50 copies/mL) through 104 weeks 4.
For PrEP, lenacapavir demonstrated remarkable efficacy with HIV incidence of 0.00-0.10 per 100 person-years compared to 0.93-2.37 in controls, representing a 96% reduction in HIV acquisition 5, 2, 6.
Dosing Regimen
Treatment Dosing (Two Options)
Option 1 (Same-Day Start):
- Day 1: 600 mg oral + 927 mg subcutaneous injection
- Day 2: 600 mg oral
- Then 927 mg subcutaneous every 6 months (26 weeks) 1
Option 2 (Delayed Injection):
- Days 1-2: 600 mg oral daily
- Day 8: 300 mg oral
- Day 15: 927 mg subcutaneous injection
- Then 927 mg subcutaneous every 6 months 1
PrEP Dosing
The first subcutaneous injection (927 mg) should be overlapped with 2 daily oral doses of lenacapavir 600 mg, followed by subcutaneous injections every 6 months 5. Barrier protection or tenofovir-based oral PrEP is recommended during the first week after initial injection, as onset of protection takes approximately 7 days 5.
Administration Details
- Route: Subcutaneous injection in the abdomen only (concentration: 309 mg/mL) 1
- Injection interval: Every 26 weeks (6 months) after loading
- Late injection management: If ≥8 weeks late (≥16 weeks from previous injection for injection 3+), "reload" with two injections 4 weeks apart before resuming every-6-month dosing 5
- Do NOT use alternative injection sites - anterior thigh injections failed to reach pharmacokinetic targets and had poor tolerability 5
Contraindications and Drug Interactions
Absolute Contraindications
Do not coadminister lenacapavir with potent inducers of CYP3A and UGT1A1 1. Specifically:
- Rifampin: Reduces lenacapavir AUC by 84% and Cmax by 55% 1
- Efavirenz: Reduces lenacapavir AUC by 56% and Cmax by 36% 1
Significant Drug Interactions Requiring Caution
Strong CYP3A/UGT1A1 inhibitors dramatically increase lenacapavir exposure:
- Atazanavir/cobicistat: Increases lenacapavir AUC by 321% and Cmax by 560% 1
- Darunavir/cobicistat: Increases lenacapavir AUC by 94% and Cmax by 130% 1
- Cobicistat alone: Increases lenacapavir AUC by 128% and Cmax by 110% 1
Lenacapavir is a moderate CYP3A inhibitor and affects other drugs:
- Midazolam: AUC increased 308-359% (avoid or reduce benzodiazepine doses) 1
- Rosuvastatin: AUC increased 31%, Cmax increased 57% (use lower statin doses) 1
- Tenofovir (from TAF): AUC increased 47% (monitor for tenofovir toxicity) 1
Monitoring Requirements
HIV Testing for PrEP Initiation
At initiation or resumption after ≥6 months hiatus, perform both:
- Fourth- or fifth-generation laboratory-based antigen-antibody assay
- HIV RNA (viral load) test with lower limit of quantification ≤50 copies/mL 5
If HIV RNA testing unavailable, may begin PrEP after negative rapid antibody test while awaiting laboratory confirmation 5. This dual testing approach prevents starting PrEP during acute HIV infection when antibody tests may be falsely negative.
Treatment Monitoring
For heavily treatment-experienced patients on lenacapavir:
- Viral load monitoring at regular intervals (specific frequency not defined in guidelines, but typically every 3-6 months in clinical practice)
- CD4 count monitoring: Mean increase of 122 cells/µL observed at 104 weeks 4
- Resistance testing if virologic failure occurs
Safety Monitoring
Injection site reactions (ISRs) are the most common adverse event:
- Occur in 31-63% of patients 7, 8, 3
- Usually mild-moderate and decrease over time 5, 2
- Led to discontinuation in only 1.2% of patients 6
- No grade 3/4 treatment-related adverse events reported 4, 8
No routine laboratory safety monitoring is required beyond standard HIV care, as lenacapavir showed no clinically significant effects on renal or hepatic function 1.
Special Populations
No dose adjustment needed for:
- Age 18-78 years
- Any sex, race, or ethnicity
- Body weight 41.4-164 kg
- Severe renal impairment (CrCl 15-29 mL/min)
- Moderate hepatic impairment (Child-Pugh B) 1
Unknown safety in:
- End-stage renal disease (though dialysis unlikely to affect levels given >98.5% protein binding)
- Severe hepatic impairment (Child-Pugh C) 1
Clinical Pearls and Pitfalls
Common Pitfalls to Avoid
Do not use anterior thigh injections - only abdominal subcutaneous administration achieves adequate drug levels 5
Do not start PrEP without proper HIV testing - fourth/fifth-generation antigen-antibody testing plus HIV RNA prevents missing acute infection 5
Do not forget the oral loading doses - the subcutaneous injection alone does not provide immediate protection; oral overlap is essential 5, 1
Do not assume immediate protection - barrier methods or oral PrEP needed for first 7 days after initial injection 5
Watch for late injections - if ≥8 weeks late, must reload with two injections 4 weeks apart rather than simply resuming 5
Resistance Considerations
Lenacapavir resistance is uncommon but can occur:
- Documented in 14 of 72 treatment-experienced patients (19%) through 104 weeks 4
- Common mutations: Q67H (HIV-1), N73D (HIV-2) 8
- Notably, 7 of 14 patients with resistance resuppressed while continuing lenacapavir 4
- Lenacapavir shows limited activity against HIV-2 - only 22% virologic suppression in HIV-2 patients versus 67% in HIV-1 8
Real-World Use Patterns
In the US OPERA cohort, 56% of patients simplified their regimen at or after lenacapavir initiation, while 31% maintained all prior antiretrovirals 7. This suggests clinicians are using lenacapavir not only for virologic control but also for regimen simplification, improved tolerability, and reduced pill burden. Among those with baseline viral suppression, 92% maintained suppression; among those with detectable viremia, 73% achieved suppression 7.
Pharmacokinetics
- Half-life: 8-12 weeks after subcutaneous injection 1
- Protein binding: >98.5% 1
- Time to peak: 77-84 days after subcutaneous injection 1
- Metabolism: Minor CYP3A and UGT1A1 pathways 1
- Excretion: 76% fecal (33% unchanged), <1% urine 1
The prolonged half-life enables twice-yearly dosing but also means drug levels persist for months after discontinuation, which has implications for resistance development if HIV exposure occurs during the tail phase.